Most common prescription drugs for prostatic hyperplasia South Korea 2016

This statistic shows the sales value of the ten most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016. During the measured year, the prescription sales of Harnal, manufactured by Astellas, amounted to around 41.78 million U.S. dollars in South Korea.

Sales value of the 10 most prescribed medications for benign prostatic hyperplasia (BPH) in South Korea in 2016

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until September 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

February 2018

Region

South Korea

Survey time period

2016

Supplementary notes

The names in the parentheses indicate the manufacturers/importers/sellers of respective medication.
Figures have been rounded.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Top pharmaceutical drugs"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.